<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Left ventricular assist device (LVAD) support is associated with many complications, but relatively few studies have examined the full spectrum of complications beyond infectious and <z:mp ids='MP_0001914'>bleeding</z:mp> events </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We conducted a retrospective review of patients receiving either a pulsatile-flow Heartmate XVE (HM1; Thoratec Corp., Pleasanton, CA, USA) or continuous-flow Heartmate II (HM2; Thoratec Corp.) LVAD at our institution (June 2000 to March 2012) </plain></SENT>
<SENT sid="2" pm="."><plain>Frequency and date of <z:hpo ids='HP_0003674'>onset</z:hpo> of nonbleeding, noninfectious complications were examined </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: One hundred eighty-two LVADs were implanted, 49 HM1, and 133 HM2 </plain></SENT>
<SENT sid="4" pm="."><plain>Support duration was longer for HM2s (median 358 vs. 112 days; p = 0.0003) </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, the most frequent complications were <z:hpo ids='HP_0002093'>respiratory failure</z:hpo>, <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, atrial <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, right <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0002093'>Respiratory failure</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, severe psychiatric events, and <z:hpo ids='HP_0000083'>renal failure</z:hpo> <z:hpo ids='HP_0000001'>all</z:hpo> occurred with median date of <z:hpo ids='HP_0003674'>onset</z:hpo> â‰¤ seven days postprocedure </plain></SENT>
<SENT sid="7" pm="."><plain>Right <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0001399'>hepatic failure</z:hpo>, <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, and <z:hpo ids='HP_0002326'>transient ischemic attacks</z:hpo> had a median date of <z:hpo ids='HP_0003674'>onset</z:hpo> 8 to 30 days postprocedure </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo>, <z:mp ids='MP_0010163'>hemolysis</z:mp>, and device failure occurred mostly more than a month postoperatively </plain></SENT>
<SENT sid="9" pm="."><plain>Right <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0001399'>hepatic failure</z:hpo>, and device failure were more frequent in HM1 patients than in HM2 patients </plain></SENT>
<SENT sid="10" pm="."><plain>Several events, including <z:hpo ids='HP_0001297'>stroke</z:hpo>, had much later <z:hpo ids='HP_0003674'>onset</z:hpo> in HM2 patients </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: In this 10-year review of complications following LVAD implantation, the most common adverse events tended to occur early after implantation </plain></SENT>
<SENT sid="12" pm="."><plain>As pulsatile-flow HM1s showed greater frequency and earlier <z:hpo ids='HP_0003674'>onset</z:hpo> of some adverse events, our data suggest better overall outcomes with the continuous-flow HM2s </plain></SENT>
</text></document>